stockportfolio.pro
Stocks / CERT vs ESPR
CERT vs ESPR
Certara, Inc. and Esperion Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Certara, Inc. (CERT) | Esperion Therapeutics, Inc. (ESPR) | |
|---|---|---|
| Market cap | $0.8B | $0.8B |
| Revenue (latest FY) | $418.84M | $403.13M |
| Net income (latest FY) | $-1.59M | $-22.68M |
| Revenue growth (5y CAGR) | 11.5% | 12.1% |
| Net margin | -0.4% | -5.6% |
| Return on equity | -0.2% | 7.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CERT — free Open ESPR — freeFrequently asked questions
Which is bigger, CERT or ESPR?
Esperion Therapeutics, Inc. is larger by market capitalization — $0.8B versus $0.8B.
Which grows faster, CERT or ESPR?
Over the last five fiscal years, Esperion Therapeutics, Inc. grew revenue faster — 12.1%/yr versus 11.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.